Company / Operating Cash Flow
Entrada Therapeutics, Inc. Operating Cash Flow History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$41.6M
FY2025
5-year range
-$93.8M / $139.8M
FY2023-FY2025
Trend
-129.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$94M to -$42M over the past 2 years.
Based on SEC 10-K filings.
-$42M in FY2025.
Improved from -$94M to -$42M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 129.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.03 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$41.6M | -129.7% |
| FY2024 | $139.8M | +249.1% |
| FY2023 | -$93.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026